EP0077354A4 - Dialyselösung glukose, aminosäuren und insulin enthaltend. - Google Patents

Dialyselösung glukose, aminosäuren und insulin enthaltend.

Info

Publication number
EP0077354A4
EP0077354A4 EP19820901271 EP82901271A EP0077354A4 EP 0077354 A4 EP0077354 A4 EP 0077354A4 EP 19820901271 EP19820901271 EP 19820901271 EP 82901271 A EP82901271 A EP 82901271A EP 0077354 A4 EP0077354 A4 EP 0077354A4
Authority
EP
European Patent Office
Prior art keywords
solution
amino acids
insulin
liter
meq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19820901271
Other languages
English (en)
French (fr)
Other versions
EP0077354A1 (de
Inventor
Robert K Ausman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter Travenol Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Laboratories Inc filed Critical Baxter Travenol Laboratories Inc
Publication of EP0077354A1 publication Critical patent/EP0077354A1/de
Publication of EP0077354A4 publication Critical patent/EP0077354A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor

Definitions

  • peritoneal dialysis solution is inserted into the peritoneal cavity, whereby diffu ⁇ sion exchange takes place between the solution and the bloodstream across the natural body membranes, to remove by diffusion the waste products which are normally ex- creted through the kidneys, typically solutes such as sodium and chloride ions, and other materials normally excreted by the body such as urea and creatinine, and also water.
  • the nature and rate of the materials removed from the body by peritoneal dialysis is a function of the sol ⁇ utes present in the peritoneal dialysis solution.
  • Phy ⁇ siological salts are present in the peritoneal dialysis solution, such as sodium chloride, sodium lactate, and sodium acetate, generally at slightly hypotonic concen- trations (but for calcium) so that excess concentrations of the ions forming such salts in the bloodstream will diffuse into the peritoneal dialysis solution for removal.
  • solutes may be added to generate the nec ⁇ essary osmotic pressure.
  • this solute is a sugar such as glucose, which may normally be present in peritoneal dialysis solutions in a concentration of about 0.5 to 4.25 percent by weight.
  • peritoneal dialysis solution diffuses into the bloodstream to a significant extent. Accordingly, while the system is safe and effective for increasing the ultrafiltration dur ⁇ ing peritoneal dialysis, the patient receives a heavy dose of calories during each peritoneal dialysis procedure from
  • ingredients of the solution of this invention are all individually known as ingredients of parenteral
  • the addition of insulin to the solution provides benefits relating to both the metabolizing of glucose, and also the assimila ⁇ tion of amino acids into the cells to form a protein. While these are known functions of insulin, it has not been previously used as a combined ingredient in a dialy- sis solution to simultaneously facilitate the metabolizing of amino acids and glucose or other sugar by the patient.
  • measured amounts of amino acids and glucose or other sugar may be used in the peritoneal dialysis solution, initially for the purpose of increasing the osmolarity of the solution so that ultrafiltration of water may take place from the patient during the dialysis procedure.
  • the insulin serves to facilitate the metabolizing of glucose and amino acids which diffuse from the dialysis solution into the bloodstream of the patient.
  • the amount of insulin required can be predetermined beforehand, depending upon the concentrations of amino acids and sugar present, so that a premeasured solution may be provided for a dialysis procedure, for the combined benefits of dialyzing uremic patients who are diabetic and protein starved, so that the patients receive the optimum amount of insulin to f cilitate their metabolism of the amino acids and sugar provided, without the need in the case of diabetic patients to recalculate their normal administra ⁇ tion schedule of insulin. Also, less sugar may be used, being partly or completely replaced by amino acids.
  • a medical solution for administration to patients, typically for use as a dialysis solution. It comprises a water solution having the presence of physiological salts in sufficient concentration to be osmotically compatible with blood. There is also included a mixture of physiological amino acids, and optionally a source of carbohydrate nutrition such as glucose is present. There is also added insulin in proportions sufficient to permit the substantial assimilation of both the source of carbohy ⁇ drate nutrition when present, and amino acids by a dia ⁇ betic or other type of patient. If desired, other sugars such as fructose may be used as an equivalent substitute for glucose. Also glucose polymers and the like, or a sugar alcohol such as glycerol may be used as the source of carbohydrate nutrition.
  • glucose as used below is intended to include these equivalent materials as alternatives.
  • the solution is particularly contemplated for use as a peritoneal dialysis solution where a relatively high osmolarity is desirable to stimulate ultrafiltration of water from a patient, but it may also be used as an intra- venous nutrient solution or a he odialysis solution.
  • the mixture of glucose and amino acids serves as an osmolarity-promoting agent to provide higher ultrafiltration.
  • the amino acids, glucose, and insulin diffuse into the bloodstream of the patient.
  • the glucose and amino acids pro ⁇ vide nutrition to the patient, with the assimilation of the glucose and amino acids being facilitated by the presence of insulin to help reverse the typically negative nitrogen balance found in persons in renal failure while treated under prior art procedures.
  • the solution also assists in the management of diabetic patients, since the premeasured amount of insulin present in the medical solution facilitates the assimila ⁇ tion of the glucose present without the diabetic patient having to change the normal regime of his prescribed dosage of insulin taken conventionally.
  • the patient's entire insulin requirements can be taken care of by the insulin in the solution of this invention, if desired, to reduce the numbers of injections that the patient must subject himself to in the instance that the patient is engaging in a continuous and daily regime of CAPD, with several changes of dialysis solution being made every day.
  • solutions of this invention may be premixed, typ- ically with a separate sterilization of different solution portions containing respectively the glucose and amino acids in a separate, interconnected container system, followed by mixing without breaching the sterile conditions of the system. This avoids the known incompatability problems encountered on sterilizing a mixture of sugar
  • glucose and amino acid solutions may be separately sterilized in separate containers, and then brought together by the use of a sterile connector system similar to that shown in U.S. Patent No. 4,157,723 or the like, providing a reliably sterile connection per ⁇ mitting the sterile mixing of the two solutions to form the medical solution of this invention.
  • glucose and amino acid solutions may be premixed shortly before infusion under conditions which are substantially aseptic although not necessarily completely sterile.
  • from 0.5 to 4 grams per liter of glucose or an equivalent material may be present in the solution of this invention, in conjunction with from 1 to 4 grams per liter of a mixture of amino acids preferably containing at least 50 percent by weight of essential amino acids, optionally including other nonessential amino acids as may be desired.
  • a mixture of amino acids preferably containing at least 50 percent by weight of essential amino acids, optionally including other nonessential amino acids as may be desired.
  • the mixture of amino acids found in Travasol® amino acid solutions sold by Travenol Laboratories, Inc. of Deerfield, Illinois may be utilized to formulate the solutions of this invention, or any other available mixture of amino acids for parenteral administration may be used.
  • Added to this may preferably be 1 to 10 units of insulin per liter of solution for the beneficial purposes described above.
  • amino acids is intended to include suitable short-chain polypeptides as equivalent substitute materials for the free amino acids.
  • concentration of glucose can be re ⁇ substituted in this manner from a typical high glucose concen ⁇ tration of up to 4.25 percent as found in prior art solutions, while the osmolarity of the solution can remain elevated because of the presence of the amino acid.
  • a dialysis solution having the desired high osmolarity coupled with a better nutrient mix for the patient, may be provided in which the nutrients are better assimilated or metabolized by the patient because of the presence of the insulin.
  • the medical solution of this invention may comprise a water solution at a pH of 5.0 to 7.4, con ⁇ taining from 130 to 140 mEq/liter of sodium, 100 to 140 mEq/liter of chloride, 0 to 6 mEq/liter of calcium, 0 to 4 mEq/liter of magnesium, and, if desired, other ions, for example, 30 to 40 mEq/liter of bicarbonate precursors such as one or more of lactate, acetate, malate, and/or succinate ions.
  • the above ions may be provided by the addition of conventional physiological salts such as sodium chloride, calcium chloride, sodium lactate, sodium acetate, and traces of other salts such as potassium chloride, magne ⁇ sium chloride, and the like, added in accordance with the known requirements for proper ion balance in a dialysis solution.
  • physiological salts such as sodium chloride, calcium chloride, sodium lactate, sodium acetate, and traces of other salts such as potassium chloride, magne ⁇ sium chloride, and the like, added in accordance with the known requirements for proper ion balance in a dialysis solution.
  • the osmolarity of the solutions of this invention is generally preferable for the osmolarity of the solutions of this invention to be from 272 to 700 milliosmols per liter, preferably 279 to 480 milliosmols per liter.
  • the bicarbonate precursor acid ions mentioned above, as well as other acid ions of the Krebs cycle, may be added to also offer advantages in pH control of the peri ⁇ toneal dialysis solution of this invention.
  • the sodium or potassium salts of such ions, for exmaple, may be used for this purpose, or the free acids.
  • Sulfhydryl-type antioxidants for example N-acyl cysteine, may be also added to stabilize the amino acids in the peritoneal dialysis solution of this invention.
  • a peritoneal dialysis solution in ac ⁇ cordance with this invention may be provided by adding, per liter of water, 5.55 grams of sodium chloride, 3.92 grams of sodium lactate, 0.257 gram of calcium chloride dihydrate, 0.152 gram of magnesium chloride hexahydrate, 1 gram of glucose, 3.25 grams of a mixture of essential and other amino acids, and 3 units per liter of insulin.
  • ⁇ 5.55 grams of sodium chloride, 3.92 grams of sodium lactate, 0.257 gram of calcium chloride dihydrate, 0.152 gram of magnesium chloride hexahydrate, 1 gram of glucose, 3.25 grams of a mixture of essential and other amino acids, and 3 units per liter of insulin.
  • the various components of the solu- tions may be broken down into two solutions with the glu ⁇ cose being in one portion and the amino acids in the other, for separate sterilization.
  • Each of the solutions may be in a conventional flexible, collapsible container con ⁇ nected by tubing and sealed with any desired internal tubing seal, so that the solution may be separately ster ⁇ ilized. Thereafter, the internal tubing seal may be broken and the solutions may be joined together into the single solution of this invention without disruption of the ster ⁇ ile seal of the solution.
  • the solution container ultimately used to store the mixed, sterile solution of this invention may be stored in a container of the design illustrated, for example, in U.S. Patent No. 4,232,721, being made out of a substantially polypropylene plastic.
  • the connection tube to the other container may be heat-sealed shut and severed after mix ⁇ ing of the containers in conventional manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19820901271 1981-04-27 1982-03-25 Dialyselösung glukose, aminosäuren und insulin enthaltend. Withdrawn EP0077354A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25810581A 1981-04-27 1981-04-27
US258105 1981-04-27

Publications (2)

Publication Number Publication Date
EP0077354A1 EP0077354A1 (de) 1983-04-27
EP0077354A4 true EP0077354A4 (de) 1983-09-30

Family

ID=22979115

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19820901271 Withdrawn EP0077354A4 (de) 1981-04-27 1982-03-25 Dialyselösung glukose, aminosäuren und insulin enthaltend.

Country Status (6)

Country Link
EP (1) EP0077354A4 (de)
JP (1) JPS58500563A (de)
CA (1) CA1168582A (de)
IT (1) IT1151741B (de)
WO (1) WO1982003773A1 (de)
ZA (1) ZA822608B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574085A (en) * 1981-05-15 1986-03-04 Baxter Travenol Laboratories, Inc. Method for using dialysis solution containing glycerol
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
DE3812525C1 (de) * 1988-04-15 1989-06-22 Fresenius Ag, 6380 Bad Homburg, De
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5238684A (en) * 1988-07-29 1993-08-24 University Of Florida Compositions and methods for achieving improved physiological response to exercise
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
WO1992011773A1 (en) * 1990-12-31 1992-07-23 University Of Florida Compositions and methods for achieving improved physiological response to exercice
US5290766A (en) * 1991-02-18 1994-03-01 The National Heart Foundation Of New Zealand Cardioplegic compositions
DE4134723C1 (de) * 1991-10-21 1993-02-11 Pfrimmer Kabi Gmbh & Co Kg, 8520 Erlangen, De
SE9103395D0 (sv) * 1991-11-18 1991-11-18 Gambro Ab System med anvaendning av ensteril medicinsk loesning innehaallande glukos eller glukosliknande aemnen samt en loesning avsedd foer detta system
CA2129998C (en) * 1992-12-22 2006-07-11 Leo Martis Improved amino acid solutions for treatment of peritoneal dialysis patients
US6380163B1 (en) † 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
CN1110112A (zh) * 1994-04-11 1995-10-18 贾增申 一种氨基酸固体饮料及其制备方法
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
ES2208884T3 (es) * 1996-01-25 2004-06-16 Schering Aktiengesellschaft Soluciones mejoradas de agentes de contraste para la administracion intravasal.
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
SE9703775L (sv) * 1997-10-16 1999-04-17 Pharmalink Baslaekemedel Ab Framställning av sterial lösningar som innehåller glukos
JP2003514014A (ja) * 1999-11-15 2003-04-15 ティー ガンガル，ハナマラディ 静脈注入のためのブドウ糖およびインスリン含有液体配合物
WO2002049636A1 (en) * 2000-12-19 2002-06-27 Rajagopal Thiruvengadam An antidiabetic composition of amino acids
SE523153C2 (sv) * 2000-12-28 2004-03-30 Gambro Lundia Ab Metod för detoxifiering av medicinsk lösning
JP5433424B2 (ja) * 2007-03-02 2014-03-05 シュトプロテック ゲーエムベーハー グルタミン残基を含む炭水化物系腹膜透析液
AU2009268742C1 (en) 2008-07-07 2013-11-28 Pentec Health, Inc. Nutritive compositions and methods of using same
GB2489163A (en) 2010-01-04 2012-09-19 Pentec Health Inc Nutritive compositions and methods of using same
WO2025087731A1 (en) 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920838A (en) * 1973-09-04 1975-11-18 Flatt Jean Pierre Amino acid therapy
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4239041A (en) * 1977-03-03 1980-12-16 Moncrief Jack W Method for continuous ambulatory peritoneal dialysis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738299A (en) * 1953-05-11 1956-03-13 Abbott Lab Stable nutritive amino acid compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920838A (en) * 1973-09-04 1975-11-18 Flatt Jean Pierre Amino acid therapy
US4239041A (en) * 1977-03-03 1980-12-16 Moncrief Jack W Method for continuous ambulatory peritoneal dialysis
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states

Also Published As

Publication number Publication date
ZA822608B (en) 1983-03-30
CA1168582A (en) 1984-06-05
JPS58500563A (ja) 1983-04-14
EP0077354A1 (de) 1983-04-27
WO1982003773A1 (en) 1982-11-11
IT1151741B (it) 1986-12-24
IT8220921A0 (it) 1982-04-23

Similar Documents

Publication Publication Date Title
CA1168582A (en) Dialysis solution containing glucose, amino acids and insulin
KR101119334B1 (ko) 투석 요법용 중탄산염-기재 용액
AU638527B2 (en) Histidine buffered peritoneal dialysis solution
CN101843634B (zh) 含艾考糊精的生物相容性透析流体
EP1753437B1 (de) Peritonealdialyselösungen auf bicarbonatbasis
US5945449A (en) Sterile bicarbonate concentrate
US4574085A (en) Method for using dialysis solution containing glycerol
US20020077580A1 (en) Sterile low bicarbonate dialysis concentrate solutions
Ing et al. Bicarbonate-buffered peritoneal dialysis
AU8392382A (en) Dialysis solution containing glucose, amino acids & insulin
EP3703759A1 (de) Verfahren und system zur bereitstellung von peritonealdialyseflüssigkeiten mit unterschiedlichen natriumkonzentrationen
US12138280B2 (en) Method and system for providing peritoneal dialysis fluids with variable potassium concentrations
CA2219822C (en) Sterile bicarbonate concentrate
Pascual et al. Hemofiltration in children with renal failure
Guillot et al. Continuous ambulatory peritoneal dialysis in pediatrics: preliminary results on 18 months experience
Bonzel et al. Practical Problems with Continuous Ambulatory Peritoneal Dialysis in Children
HK1088535B (en) Biocompatible dialysis fluids containing icodextrins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19821104

AK Designated contracting states

Designated state(s): BE CH DE FR GB LI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19841213

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AUSMAN, ROBERT K.